CO2019002839A2 - Inhibidores de cinasa de cremallera de leucina dual (dlk) para el tratamiento de enfermedades - Google Patents
Inhibidores de cinasa de cremallera de leucina dual (dlk) para el tratamiento de enfermedadesInfo
- Publication number
- CO2019002839A2 CO2019002839A2 CONC2019/0002839A CO2019002839A CO2019002839A2 CO 2019002839 A2 CO2019002839 A2 CO 2019002839A2 CO 2019002839 A CO2019002839 A CO 2019002839A CO 2019002839 A2 CO2019002839 A2 CO 2019002839A2
- Authority
- CO
- Colombia
- Prior art keywords
- disease
- dlk
- injury
- diseases
- leucine zipper
- Prior art date
Links
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title abstract 4
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 title abstract 2
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 title abstract 2
- 201000010099 disease Diseases 0.000 title abstract 2
- 230000009977 dual effect Effects 0.000 title abstract 2
- 229940043355 kinase inhibitor Drugs 0.000 title 1
- 239000003757 phosphotransferase inhibitor Substances 0.000 title 1
- 108091000080 Phosphotransferase Proteins 0.000 abstract 2
- 238000002512 chemotherapy Methods 0.000 abstract 2
- 230000006378 damage Effects 0.000 abstract 2
- 208000035475 disorder Diseases 0.000 abstract 2
- 201000001119 neuropathy Diseases 0.000 abstract 2
- 230000007823 neuropathy Effects 0.000 abstract 2
- 102000020233 phosphotransferase Human genes 0.000 abstract 2
- 208000024827 Alzheimer disease Diseases 0.000 abstract 1
- 102000014461 Ataxins Human genes 0.000 abstract 1
- 108010078286 Ataxins Proteins 0.000 abstract 1
- 206010068597 Bulbospinal muscular atrophy congenital Diseases 0.000 abstract 1
- 206010008025 Cerebellar ataxia Diseases 0.000 abstract 1
- 208000027104 Chemotherapy-Related Cognitive Impairment Diseases 0.000 abstract 1
- 208000032131 Diabetic Neuropathies Diseases 0.000 abstract 1
- 201000011240 Frontotemporal dementia Diseases 0.000 abstract 1
- 101001005605 Homo sapiens Mitogen-activated protein kinase kinase kinase 12 Proteins 0.000 abstract 1
- 208000023105 Huntington disease Diseases 0.000 abstract 1
- 208000027747 Kennedy disease Diseases 0.000 abstract 1
- 208000009829 Lewy Body Disease Diseases 0.000 abstract 1
- 201000002832 Lewy body dementia Diseases 0.000 abstract 1
- 102100025180 Mitogen-activated protein kinase kinase kinase 12 Human genes 0.000 abstract 1
- 208000012902 Nervous system disease Diseases 0.000 abstract 1
- 208000025966 Neurological disease Diseases 0.000 abstract 1
- 206010033799 Paralysis Diseases 0.000 abstract 1
- 208000018737 Parkinson disease Diseases 0.000 abstract 1
- 208000009415 Spinocerebellar Ataxias Diseases 0.000 abstract 1
- 208000006011 Stroke Diseases 0.000 abstract 1
- 208000030886 Traumatic Brain injury Diseases 0.000 abstract 1
- 208000027418 Wounds and injury Diseases 0.000 abstract 1
- 208000006269 X-Linked Bulbo-Spinal Atrophy Diseases 0.000 abstract 1
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 abstract 1
- 201000004562 autosomal dominant cerebellar ataxia Diseases 0.000 abstract 1
- 210000003169 central nervous system Anatomy 0.000 abstract 1
- 230000001684 chronic effect Effects 0.000 abstract 1
- 208000010877 cognitive disease Diseases 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 208000014674 injury Diseases 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 230000004770 neurodegeneration Effects 0.000 abstract 1
- 208000015122 neurodegenerative disease Diseases 0.000 abstract 1
- 230000000926 neurological effect Effects 0.000 abstract 1
- 210000002569 neuron Anatomy 0.000 abstract 1
- 150000002823 nitrates Chemical class 0.000 abstract 1
- 230000002093 peripheral effect Effects 0.000 abstract 1
- 210000001428 peripheral nervous system Anatomy 0.000 abstract 1
- 208000033808 peripheral neuropathy Diseases 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 230000000144 pharmacologic effect Effects 0.000 abstract 1
- 230000000750 progressive effect Effects 0.000 abstract 1
- 208000020431 spinal cord injury Diseases 0.000 abstract 1
- 230000009529 traumatic brain injury Effects 0.000 abstract 1
- 230000000472 traumatic effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
- C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- General Chemical & Material Sciences (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Psychology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Psychiatry (AREA)
- Physical Education & Sports Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Abstract
En el presente documento se dan a conocer compuestos que inhiben la actividad de cinasa de la cinasa de cremallera de leucina dual (DLK) (MAP3K12), composiciones farmacéuticas y métodos de tratamiento de enfermedades mediadas por DLK, tales como enfermedades neurológicas que resultan de lesión traumática al sistema nervioso central y neuronas del sistema nervioso periférico (por ejemplo, apoplejía, lesión cerebral traumática, lesión de médula espinal), o que resultan de un padecimiento neurodegenerativo crónico (por ejemplo, enfermedad de Alzheimer, demencia frontotemporal, enfermedad de Parkinson, enfermedad de Huntington, esclerosis lateral amiotrófica, ataxia espinocerebelar, parálisis supranuclear progresiva, enfermedad de cuerpos de Lewy, enfermedad de Kennedy y otros padecimientos relacionados), de neuropatías que resultan de daño neurológico (neuropatía periférica inducida por quimioterapia, neuropatía diabética y trastornos relacionados) y de trastornos cognitivos ocasionados por intervención farmacológica (por ejemplo, trastorno cognitivo inducido por quimioterapia, también conocido como quimiocerebro).
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662380822P | 2016-08-29 | 2016-08-29 | |
| PCT/US2017/048941 WO2018044808A1 (en) | 2016-08-29 | 2017-08-28 | Inhibitors of dual leucine ziper (dlk) kinase for the treatment of disease |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CO2019002839A2 true CO2019002839A2 (es) | 2019-04-30 |
Family
ID=61240329
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CONC2019/0002839A CO2019002839A2 (es) | 2016-08-29 | 2019-03-27 | Inhibidores de cinasa de cremallera de leucina dual (dlk) para el tratamiento de enfermedades |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20180057507A1 (es) |
| EP (1) | EP3503889A1 (es) |
| JP (1) | JP2019528319A (es) |
| KR (1) | KR20190040068A (es) |
| CN (1) | CN109789132A (es) |
| AU (1) | AU2017321313A1 (es) |
| BR (1) | BR112019004243A2 (es) |
| CA (1) | CA3035195A1 (es) |
| CL (1) | CL2019000534A1 (es) |
| CO (1) | CO2019002839A2 (es) |
| EA (1) | EA201990450A1 (es) |
| EC (1) | ECSP19021843A (es) |
| MX (1) | MX2019002444A (es) |
| WO (1) | WO2018044808A1 (es) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10093664B2 (en) | 2016-12-08 | 2018-10-09 | Board Of Regents, The University Of Texas System | Bicyclo[1.1.1]pentane inhibitors of dual leucine zipper (DLK) kinase for the treatment of disease |
| US11560366B2 (en) * | 2019-10-21 | 2023-01-24 | Board Of Regents, The University Of Texas System | Bicyclo[1.1.1]pentane inhibitors of dual leucine zipper (DLK) kinase for the treatment of disease |
| AU2021336300A1 (en) | 2020-09-02 | 2023-03-16 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | LZK-targeting degraders and methods of use |
| JP2023544892A (ja) * | 2020-10-13 | 2023-10-25 | ザ・ジョンズ・ホプキンス・ユニバーシティー | 置換４－（［１，２，４］トリアゾロ［１，５－ａ］ピリジン－６－イル）チオフェン－２－カルボキサミド誘導体及びその使用 |
| CN114605497B (zh) * | 2021-02-10 | 2023-04-28 | 北京欣安诚科技有限公司 | 一种dapk1磷酸化底物的人工小分子干扰肽及其制药用途 |
| KR20240055041A (ko) * | 2021-09-01 | 2024-04-26 | 더 유나이티드 스테이츠 오브 아메리카, 애즈 레프리젠티드 바이 더 세크러테리, 디파트먼트 오브 헬스 앤드 휴먼 서비시즈 | 혼합 계통 키나제 억제제 및 억제제의 사용 방법 |
| CN115770239B (zh) * | 2022-12-05 | 2024-01-30 | 南京中医药大学 | 呋喃并色酮及药学上可接受的盐在制备治疗周围神经病变的药物中的应用 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7163924B2 (en) * | 2003-04-25 | 2007-01-16 | Chiron Corporation | Ketolide derivatives |
| CA2523134A1 (en) * | 2003-04-25 | 2004-11-11 | Chiron Corporation | Pyridyl substituted ketolide antibiotics |
| TW200944520A (en) * | 2008-01-29 | 2009-11-01 | Glaxo Group Ltd | Spiro compounds as NPY Y5 receptor antagonists |
| FR2928923B1 (fr) * | 2008-03-21 | 2010-04-23 | Sanofi Aventis | Derives polysubstitues de 2-heteroaryl-6-phenyl-imidazo °1,2-a!pyridines, leur preparation et leur application en therapeutiques |
| US9073895B2 (en) * | 2010-12-16 | 2015-07-07 | Boehringer Ingelheim International Gmbh | Biarylamide inhibitors of leukotriene production |
| CN104271566B (zh) * | 2012-05-22 | 2017-05-31 | 霍夫曼-拉罗奇有限公司 | 取代的联吡啶胺及其用途 |
| JP6199991B2 (ja) * | 2013-01-18 | 2017-09-20 | エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ | ３置換ピラゾール及びｄｌｋ阻害剤としての使用 |
| EA038235B1 (ru) * | 2013-05-01 | 2021-07-28 | Ф.Хоффманн-Ля Рош Аг | Бигетероарильные соединения и их применения |
| MX2016008110A (es) * | 2013-12-20 | 2016-08-19 | Hoffmann La Roche | Derivados de pirazol como inhibidores de la cinasa de cremallera de leucina dual (dlk) y usos de los mismos. |
-
2017
- 2017-08-28 WO PCT/US2017/048941 patent/WO2018044808A1/en active Application Filing
- 2017-08-28 EP EP17847316.1A patent/EP3503889A1/en not_active Withdrawn
- 2017-08-28 KR KR1020197008981A patent/KR20190040068A/ko unknown
- 2017-08-28 CA CA3035195A patent/CA3035195A1/en not_active Abandoned
- 2017-08-28 BR BR112019004243A patent/BR112019004243A2/pt not_active Application Discontinuation
- 2017-08-28 JP JP2019531562A patent/JP2019528319A/ja active Pending
- 2017-08-28 MX MX2019002444A patent/MX2019002444A/es unknown
- 2017-08-28 US US15/688,554 patent/US20180057507A1/en not_active Abandoned
- 2017-08-28 AU AU2017321313A patent/AU2017321313A1/en not_active Abandoned
- 2017-08-28 CN CN201780057801.3A patent/CN109789132A/zh active Pending
- 2017-08-28 EA EA201990450A patent/EA201990450A1/ru unknown
-
2019
- 2019-02-28 CL CL2019000534A patent/CL2019000534A1/es unknown
- 2019-03-27 CO CONC2019/0002839A patent/CO2019002839A2/es unknown
- 2019-03-28 EC ECSENADI201921843A patent/ECSP19021843A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CA3035195A1 (en) | 2018-03-08 |
| US20180057507A1 (en) | 2018-03-01 |
| EP3503889A1 (en) | 2019-07-03 |
| ECSP19021843A (es) | 2019-05-31 |
| WO2018044808A1 (en) | 2018-03-08 |
| CL2019000534A1 (es) | 2019-08-02 |
| JP2019528319A (ja) | 2019-10-10 |
| BR112019004243A2 (pt) | 2019-06-04 |
| KR20190040068A (ko) | 2019-04-16 |
| CN109789132A (zh) | 2019-05-21 |
| MX2019002444A (es) | 2019-09-02 |
| AU2017321313A1 (en) | 2019-03-21 |
| EA201990450A1 (ru) | 2019-07-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO2019006785A2 (es) | Inhibidores biciclo[1.1.1]pentano de la cinasa de cremallera de leucina dual (dlk) para el tratamiento de enfermedades | |
| CO2019002839A2 (es) | Inhibidores de cinasa de cremallera de leucina dual (dlk) para el tratamiento de enfermedades | |
| BR112018068538A2 (pt) | composto, medicamento, uso de um composto, e, métodos para inibir monoacilglicerol lipase e para profilaxia ou tratamento de doença ou transtorno. | |
| DOP2018000204A (es) | Moduladores alostéricos de receptores de acetilcolina nicotínicos | |
| DOP2018000031A (es) | DERIVADOS DE 1,1,1-TRIFLUORO-3-HIDROXIPROPAN-2-IL CARBAMATO y DERIVADOS DE 1,1,1-TRIFLUORO-4-HIDROXIBUTAN-2-IL CARBAMATO COMO INHIBIDORES DE MAGL | |
| AR110747A1 (es) | Compuestos de 5-metil-1,2,4-oxadiazol-3-ilo | |
| MX2016002644A (es) | Composicion que comprende torasemida y baclofeno para tratar trastornos neurologicos. | |
| CO2020003932A2 (es) | Compuesto heterocíclico | |
| EA201691602A1 (ru) | Комбинация баклофена, акампросата и среднецепочечных триглицеридов для лечения неврологических расстройств | |
| EA201300975A1 (ru) | Новые композиции для лечения неврологических заболеваний | |
| CR20170187A (es) | 2-Amino-3,5-difluoro-6-metil-6-fenil-3,4,5,6-tetrahidropiridinas en calidad de inhibidores de BACE1 para el tratamiento de la enfermedad de Alzheimer | |
| CL2015000096A1 (es) | Compuestos derivados de 4-metil-2,3,5,9,9b-pentaaza-ciclopenta[a]naftalenos, inhibidores de fosfodiestearasa 2 y/o 10; composicion farmaceutica; y su uso para prevencion o tratamiento de enfermedades del sistema nervioso, como deficiencia cognitiva, demencia, trastornos de ansiedad, enf. de alzheimer, enf. de parkinson, otros | |
| CL2021002877A1 (es) | Inhibidores del gen kcnt1, composiciones y usos para trastornos neurológicos | |
| ECSP20067907A (es) | Moduladores alostéricos de espiropiperidina de receptores nicotínicos de acetilcolina | |
| MX2019001421A (es) | Composiciones de reelina para el tratamiento de trastornos neurologicos. | |
| BR112015015509A2 (pt) | composto farmacêutico para a prevenção e tratamento de uma doença ou desordem cognitiva, neuro degenerativa ou doença neuronal | |
| MX2020003844A (es) | Compuesto y composición para su uso en el tratamiento preventivo y/o curativo de enfermedades del sistema nervioso central caracterizadas por una disminución de la plasticidad neuronal, en particular caracterizadas por una disminución de la plasticidad sináptica. | |
| MX2016000724A (es) | Compuestos de reserva de los receptores activados del proliferador de peroxisoma (ppar) para el tratamiento de enfermedades metabolicas. | |
| MX2018013405A (es) | Derivado de benzodiazepina con actividad sobre el sistema nervioso central y vascular. | |
| WO2017103892A3 (en) | Composition for treating and preventing neurological diseases, neuroinflammation, and alzheimer's disease | |
| WO2015189830A9 (en) | Dual inhibitor compounds for use in the treatment of neurodegenerative disorders and alzheimer's disease | |
| WO2014111525A3 (en) | Combination therapies for treating nervous system diseases | |
| MX2019013717A (es) | Plasma de origen animal o fracciones del mismo para usarse en el tratamiento contra trastornos del deterioro cognitivo en humanos y animales de compañia. | |
| AR104029A1 (es) | Métodos y composiciones para la administración intravenosa de fumaratos para el tratamiento de enfermedades neurológicas | |
| MX2016003878A (es) | Composicion, proceso de produccion y uso de composicion para tratamiento de desordenes del sistema nervioso central. |